David Curtis Egberg

Title: David Curtis Egberg: Innovator in Diabetes Management

Introduction

David Curtis Egberg is a notable inventor based in Shorewood, MN (US). He has made significant contributions to the field of diabetes management through his innovative patent. His work focuses on the therapeutic use of L-arginine in conjunction with meals for individuals with Type II diabetes mellitus.

Latest Patents

David Curtis Egberg holds a patent for "Oral arginine and insulin secretion." This patent describes a method of administering a therapeutically effective amount of L-arginine, or a physiologically acceptable salt thereof, orally as a food supplement. The method is particularly beneficial for individuals with Type II diabetes who are not on insulin or other medications for glycemic control. The patent highlights that when 3 g to 15 g of L-arginine is ingested with a meal, it decreases the concentration of insulin generated compared to the same meal without L-arginine. Additionally, it shows that the concentration of glucose in the blood is decreased, indicating that available insulin can effectively sensitize cells, mimicking the function of normal cells in non-diabetic individuals. Notably, the ingestion of L-arginine alone does not produce a measurable increase in insulin secretion in diabetic patients.

Career Highlights

David Curtis Egberg is associated with Novartis Nutrition AG, where he continues to contribute to advancements in nutritional science and diabetes management. His innovative approach to using L-arginine as a dietary supplement showcases his commitment to improving the quality of life for individuals with diabetes.

Collaborations

David has worked alongside notable colleagues such as Sharon Marie Gohman and Lester David Michels, contributing to a collaborative environment that fosters innovation and research in the field of nutrition and diabetes.

Conclusion

David Curtis Egberg's work in the development of oral L-arginine as a therapeutic supplement represents a significant advancement in diabetes management. His patent and ongoing contributions to Novartis Nutrition AG highlight his dedication to improving health outcomes for individuals with Type II diabetes.